Novo Nordisk Statistics

Total Valuation

Novo Nordisk has a market cap or net worth of GBP 167.56 billion. The enterprise value is 176.86 billion.

Market Cap	167.56B
Enterprise Value	176.86B

Important Dates

The last earnings date was Wednesday, August 6, 2025.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	Mar 31, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.57%
Shares Change (QoQ)	+0.01%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	3.19B

Valuation Ratios

The trailing PE ratio is 13.13 and the forward PE ratio is 12.16.

PE Ratio	13.13
Forward PE	12.16
PS Ratio	4.67
PB Ratio	8.68
P/TBV Ratio	24.22
P/FCF Ratio	22.36
P/OCF Ratio	12.00
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.51, with an EV/FCF ratio of 23.60.

EV / Earnings	13.86
EV / Sales	4.90
EV / EBITDA	9.51
EV / EBIT	10.28
EV / FCF	23.60

Financial Position

The company has a current ratio of 0.78, with a Debt / Equity ratio of 0.59.

Current Ratio	0.78
Quick Ratio	0.50
Debt / Equity	0.59
Debt / EBITDA	0.62
Debt / FCF	1.52
Interest Coverage	17.27

Financial Efficiency

Return on equity (ROE) is 79.17% and return on invested capital (ROIC) is 42.53%.

Return on Equity (ROE)	79.17%
Return on Assets (ROA)	21.82%
Return on Invested Capital (ROIC)	42.53%
Return on Capital Employed (ROCE)	54.12%
Revenue Per Employee	457,278
Profits Per Employee	162,817
Employee Count	77,349
Asset Turnover	0.73
Inventory Turnover	1.20

Taxes

In the past 12 months, Novo Nordisk has paid 3.41 billion in taxes.

Income Tax	3.41B
Effective Tax Rate	21.10%

Stock Price Statistics

The stock price has decreased by -61.66% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-61.66%
50-Day Moving Average	65.87
200-Day Moving Average	80.27
Relative Strength Index (RSI)	36.09
Average Volume (20 Days)	447,496

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Novo Nordisk had revenue of GBP 35.84 billion and earned 12.76 billion in profits. Earnings per share was 2.87.

Revenue	35.84B
Gross Profit	30.20B
Operating Income	17.08B
Pretax Income	16.18B
Net Income	12.76B
EBITDA	18.30B
EBIT	17.08B
Earnings Per Share (EPS)	2.87

Full Income Statement

Balance Sheet

The company has 2.18 billion in cash and 11.41 billion in debt, giving a net cash position of -9.23 billion.

Cash & Cash Equivalents	2.18B
Total Debt	11.41B
Net Cash	-9.23B
Net Cash Per Share	n/a
Equity (Book Value)	19.31B
Book Value Per Share	4.35
Working Capital	-5.15B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 13.96 billion and capital expenditures -6.47 billion, giving a free cash flow of 7.49 billion.

Operating Cash Flow	13.96B
Capital Expenditures	-6.47B
Free Cash Flow	7.49B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 84.26%, with operating and profit margins of 47.65% and 35.61%.

Gross Margin	84.26%
Operating Margin	47.65%
Pretax Margin	45.13%
Profit Margin	35.61%
EBITDA Margin	51.06%
EBIT Margin	47.65%
FCF Margin	20.91%

Dividends & Yields

This stock pays an annual dividend of 0.91, which amounts to a dividend yield of 1.83%.

Dividend Per Share	0.91
Dividend Yield	1.83%
Dividend Growth (YoY)	18.53%
Years of Dividend Growth	8
Payout Ratio	45.63%
Buyback Yield	0.57%
Shareholder Yield	2.40%
Earnings Yield	7.62%
FCF Yield	4.47%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on September 20, 2023. It was a forward split with a ratio of 2.

Last Split Date	Sep 20, 2023
Split Type	Forward
Split Ratio	2

Scores

Novo Nordisk has an Altman Z-Score of 7.82 and a Piotroski F-Score of 4.

Altman Z-Score	7.82
Piotroski F-Score	4